Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2682-2685

  Parra Ruiz, Jorge ^a   Bravo Molina, Alejandra ^b   Peña Monje, Alejandro ^a   Hernández Quero, José ^a  

^a Servicio de Enfermedades Infecciosas   (Spain)

^b HU San Cecilio   (Spain)

Author keywords

MRSA; PK PD; S. aureus

Indexed keywords

DAPTOMYCIN; LINEZOLID; METICILLIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; BIOFILM EMBEDDED BACTERIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PLANKTON; STAPHYLOCOCCUS AUREUS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BIOFILMS; DAPTOMYCIN; DRUG INTERACTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS;

EID: 84867613328     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks272     Document Type: Article

References (25)

1. Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal biofilm infections. Ann N Y Acad Sci 2011; 1241: 104-21.
2. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
3. Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005; 56: 337-43.
4. Hajdu S, Lassnigg A, Graninger W et al. Effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. J Orthop Res 2009; 27: 1361-5.
5. Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009; 63: 485-8.
6. Parra-Ruiz J, Vidaillac C, Rose WE et al. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 2010; 54: 4329-34.
7. Villar M, Marimon JM, Garcia-Arenzana JM et al. Epidemiological and molecular aspects of rifampicin-resistant Staphylococcus aureus isolated from wounds, blood and respiratory samples. J Antimicrob Chemother 2011; 66: 997-1000.
8. Tan CK, Lai CC, Liao CH et al. Increased rifampicin resistance in blood isolates of meticillin-resistant Staphylococcus aureus (MRSA) amongst patients exposed to rifampicin-containing antituberculous treatment. Int J Antimicrob Agents 2011; 37: 550-3.
9. Guay DR, Gustavson LE, Devcich KJ et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001; 23: 566-77.
10. Kelesidis T, Humphries R, Ward K et al. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn Microbiol Infect Dis 2011; 71: 286-90.
11. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
12. Ceri H, Olson ME, Stremick C et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
13. Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos 2001; 29: 1136-45.
14. Cataldo MA, Petrosillo N, Cipriani M et al. Prosthetic joint infection: recent developments in diagnosis and management. J Infect 2010; 61: 443-8.
15. Polillo M, Tascini C, Lastella M et al. A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit 2010; 32: 200-5.
16. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother 2010; 54: 5187-92.
17. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001; 23: 356-91.
18. Hobbs JK, Miller K, O'Neill AJ et al. Consequences of daptomycinmediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 2008; 62: 1003-8.
19. Baldoni D, Haschke M, Rajacic Z et al. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother 2009; 53: 1142-8.
20. El Helou OC, Berbari EF, Lahr BD et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29: 961-7.
21. Trampuz A, Zimmerli W. Diagnosis and treatment of implantassociated septic arthritis and osteomyelitis. Curr Infect Dis Rep 2008; 10: 394-403.
22. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23: 14-34.
23. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
24. Fujimura S, Sato T, Kikuchi T et al. Efficacy of clarithromycin plus vancomycin in mice with implant-related infection caused by biofilm-forming Staphylococcus aureus. J Orthop Sci 2009; 14: 658-61.
25. Furuhata M, Iwamura M, Baba S et al. Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty. Int J Urol 2003; 10: 228-30.